Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs in Rare Kidney Diseases
_↗ investors.biogen.com
News Image

Biogen is making a significant strategic pivot into immunology and rare diseases with felzartamab, an investigational anti-CD38 monoclonal antibody. This promising drug is designed to precisely target and deplete autoantibody-producing cells, offering potential for a broad range of immune-mediated conditions. Biogen is backing felzartamab with the initiation of three pivotal Phase 3 studies in 2025 for critical rare kidney diseases: late antibody-mediated rejection (AMR) in kidney transplant patients, Immunoglobulin A nephropathy (IgAN), and primary membranous nephropathy (PMN). These studies follow compelling positive results from earlier Phase 2 trials, demonstrating felzartamab's potential. The company anticipates the first readouts by 2027, with felzartamab already having received Breakthrough Therapy and Orphan Drug Designations from regulatory bodies in both the US and Europe, highlighting the significant unmet need and its therapeutic promise in these life-threatening conditions.





Log In
Sign Up